United Therapeutics Corporation

$526.58

$0.42(-0.08%)

United Therapeutics Corporation

UTHR

$526.58

$0.42(-0.08%)

United Therapeutics Corporation

UTHR

NASDAQ

$526.58

$0.42(-0.08%)

Chart

Upcoming Earnings

Next report date

Apr 29, 2026

Report period

Q2 2026

EPS Estimate

$6.72

Revenue Estimate

$809.04M

Key stats

52-Week Range$526.58

$266.98

$548.12

Market capitalization

$23.42B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

17.78

Basic EPS (TTM)

$30.13

Net income (TTM)

$1.33B

Revenue (TTM)

$3.18B

Avg. volume

444.47K

Beta (1Y)

0.86

Employees

1.31K

Market capitalization

$23.42B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

17.78

Basic EPS (TTM)

$30.13

Net income (TTM)

$1.33B

Revenue (TTM)

$3.18B

Avg. volume

444.47K

Beta (1Y)

0.86

Employees

1.31K

Screener Quick Check

About United Therapeutics Corporation

Sector

Healthcare

Industry

Biotechnology

CEO

Martine A. Rothblatt

Website

www.unither.com

Headquarters

1040 Spring Street, Silver Spring, MD, 20910

IPO Date

1999-06-17

Identifiers

ISINUS91307C1027

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address...

Related Stocks

Biogen Inc.

BIIB

$175.30Mkt Cap: $25.72B

Healthcare

Drug Manufacturers - General

ISIN:US09062X1037

Quest Diagnostics Incorporated

DGX

$198.94Mkt Cap: $22.13B

Healthcare

Medical - Diagnostics & Research

ISIN:US74834L1008

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate